Meeting
2018 Gastrointestinal Cancers Symposium
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Authors
Andrew X. Zhu
Massachusetts General Hospital, Boston, MA
Andrew X. Zhu , Richard S. Finn , Stéphane Cattan , Julien Edeline , Sadahisa Ogasawara , Daniel H. Palmer , Chris Verslype , Vittorina Zagonel , Olivier Rosmorduc , Arndt Vogel , Debashis Sarker , Gontran Verset , Stephen Lam Chan , Jennifer J. Knox , Bruno Daniele , Scot Ebbinghaus , Junshui Ma , Abby B. Siegel , Ann-Lii Cheng , Masatoshi Kudo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT02702414
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 209)
DOI
10.1200/JCO.2018.36.4_suppl.209
Abstract #
209
Poster Bd #
A6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.
First Author: Andrew X. Zhu
Poster
2020 Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
First Author: Aiwu Ruth He
Poster
2019 Gastrointestinal Cancers Symposium
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
First Author: Todd S. Crocenzi